Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant

NCT03208244 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT03208244
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03208244 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Heart Transplant
Lead sponsor
Massachusetts General Hospital
Phase
Phase 4
Overall status
Terminated
Start date
November 9, 2017
Completion date
April 28, 2021
Enrollment
40 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

end stage heart disease, hepatitis c